These results not only expand our understanding of thyroid cancer pathogenesis but also suggest that targeting the miR‐485‐5p/RASD2 axis may represent a promising therapeutic strategy for thyroid cancer treatment. The gene discussed is RASD2; the disease is thyroid cancer.